Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CDC25A | P30304 | 2/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | VDR | P11473 | 10/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5546805 | 1.00 | CYP19A1 (0.42) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL2676980 | 1.00 | CYP19A1 (0.42) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL20243735 | 0.84 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL3516877 | 0.81 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL9010563 | 0.81 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL17354893 | 0.81 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL3519758 | 0.81 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL12464613 | 0.81 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL3516879 | 0.81 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRMEN1 | |
| SCHEMBL3519755 | 0.81 | CYP19A1 (0.45) | CYP19A1CDC25ACDC25BVDRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173824-B2 | Process for producing vitamin D derivative using convergent method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100217020-A1 | PROCESS FOR PRODUCING VITAMIN D DERIVATIVE USING CONVERGENT METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1955999-A1 | METHOD FOR PRODUCING VITAMIN D DERIVATIVE BY USING CONVERGENT METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217020-A1 | PROCESS FOR PRODUCING VITAMIN D DERIVATIVE USING CONVERGENT METHOD | CYP2R1, CYP24A1, VDR | CYP19A1 50/4885CDC25A 2748/4885CDC25B 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.